Explore All 789 Divestiture Life Science Deals - Search the Database Free
M&A Deal Summary |
|
|---|---|
| Date | December 11, 2025 |
| Target | Veralox Therapeutics - VLX-1005 |
| Sector | Life Science |
| Buyer(s) | Cadrenal Therapeutics |
| Sellers(s) | Veralox Therapeutics |
| Deal Type | Divestiture |
FILTER BY
| Category | Company |
|---|---|
| Founded | 2022 |
| Sector | Life Science |
| Employees | 4 |
Cadrenal Therapeutics is a biopharmaceutical company developing transformative therapeutics to overcome the gaps in anticoagulation therapy. Cadrenal’s lead investigational product is tecarfarin, a novel oral Vitamin K antagonist anticoagulant that is designed to address unmet needs in anticoagulation therapy. Cadrenal Therapeutics was founded in 2022 and is based in Ponte Vedra, Florida.
| Deal Context for Buyer | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Life Science | 1 of 1 |
| Type: Divestiture | 1 of 1 |
| State: Maryland | 1 of 1 |
| Country: United States | 1 of 1 |
| Year: 2025 | 1 of 1 |
| Category | Company |
|---|---|
| Founded | 2017 |
| Sector | Life Science |
Veralox Therapeutics a clinical-stage biotechnology company developing a new class of therapies targeting the 12-lipoxygenase (12-LOX) pathway. Veralox Therapeutics was funded in 2017 and is based in Frederick, Maryland.
| Deal Context for Seller | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Life Science | 1 of 1 |
| Type: Divestiture | 1 of 1 |
| State: Maryland | 1 of 1 |
| Country: United States | 1 of 1 |
| Year: 2025 | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2025-01-09 |
Nudge Therapeutics
United States Nudge Therapeutics offers AMP-GMP (cGAS) inhibitor compounds. |
Buy | - |
